> top > docs > PubMed:18258746 > annotations

PubMed:18258746 JSONTXT

Annnotations TAB JSON ListView MergeView

PubTator4TogoVar

Id Subject Object Predicate Lexical cue proteinmutation
18258746_0 423-429 ProteinMutation denotes G2019S rs34637584
18258746_1 528-534 ProteinMutation denotes G2019S rs34637584
18258746_2 620-626 ProteinMutation denotes G2019S rs34637584
18258746_3 764-770 ProteinMutation denotes G2019S rs34637584

c_corpus

Id Subject Object Predicate Lexical cue
T1 2-12 2294143 denotes Drosophila
T2 2-12 504603 denotes Drosophila
T3 2-12 2294139 denotes Drosophila
T4 2-12 2294145 denotes Drosophila
T5 2-12 2294141 denotes Drosophila
T6 2-12 2294142 denotes Drosophila
T7 2-12 2294144 denotes Drosophila
T8 2-12 2294140 denotes Drosophila
T9 2-12 D004330 denotes Drosophila
T10 2-12 2080301 denotes Drosophila
T11 23-28 PR:Q5S006 denotes LRRK2
T12 23-28 PR:000003033 denotes LRRK2
T13 23-28 PR:Q5S007 denotes LRRK2
T14 36-48 D020734 denotes parkinsonism
T15 36-48 D020734 denotes parkinsonism
T17 67-74 6308 denotes leucine
T18 67-74 SO:0001437 denotes leucine
T16 67-74 CHEBI:15603 denotes leucine
T19 67-74 D007930 denotes leucine
T20 67-74 CHEBI:25017 denotes leucine
T21 67-74 D007930 denotes leucine
T22 80-86 SO:0001068 denotes repeat
T23 95-100 PR:Q5S006 denotes LRRK2
T24 95-100 PR:000003033 denotes LRRK2
T25 95-100 PR:Q5S007 denotes LRRK2
T26 102-106 SO:0000704 denotes gene
T27 113-123 D000067562 denotes late-onset
T28 113-123 D000067562 denotes late-onset
T29 124-142 C566739 denotes autosomal dominant
T34 143-162 D010300 denotes Parkinson's disease
T35 143-162 D010300 denotes Parkinson's disease
T38 255-260 PR:Q5S006 denotes LRRK2
T39 255-260 PR:000003033 denotes LRRK2
T40 255-260 PR:Q5S007 denotes LRRK2
T49 324-328 P56470 denotes GAL4
T50 324-328 Q3T0D6 denotes GAL4
T51 324-328 PR:P04386 denotes GAL4
T52 324-328 P38552 denotes GAL4
T54 324-328 PR:Q6GXJ1 denotes GAL4
T55 324-328 Q6QLR3 denotes GAL4
T56 324-328 Q6GXJ1 denotes GAL4
T57 324-328 Q8K419 denotes GAL4
T58 324-328 PR:000009773 denotes GAL4
T60 324-328 Q29058 denotes GAL4
T53 324-328 CHEBI:62999 denotes GAL4
T59 324-328 CHEBI:60188 denotes GAL4
T61 352-362 SO:0000781 denotes transgenic
T62 363-373 2294143 denotes Drosophila
T63 363-373 504603 denotes Drosophila
T64 363-373 2294139 denotes Drosophila
T65 363-373 2294145 denotes Drosophila
T66 363-373 2294141 denotes Drosophila
T67 363-373 2294142 denotes Drosophila
T68 363-373 2294144 denotes Drosophila
T69 363-373 2294140 denotes Drosophila
T70 363-373 D004330 denotes Drosophila
T71 363-373 2080301 denotes Drosophila
T72 392-401 SO:0000817 denotes wild-type
T73 402-407 D006801 denotes human
T74 408-413 PR:Q5S006 denotes LRRK2
T75 408-413 PR:000003033 denotes LRRK2
T76 408-413 PR:Q5S007 denotes LRRK2
T77 417-422 PR:Q5S006 denotes LRRK2
T78 417-422 PR:000003033 denotes LRRK2
T79 417-422 PR:Q5S007 denotes LRRK2
T80 447-455 SO:0000109 denotes mutation
T81 497-506 SO:0000817 denotes wild-type
T82 507-512 D006801 denotes human
T83 513-518 PR:Q5S006 denotes LRRK2
T84 513-518 PR:000003033 denotes LRRK2
T85 513-518 PR:Q5S007 denotes LRRK2
T86 522-527 PR:Q5S006 denotes LRRK2
T87 522-527 PR:000003033 denotes LRRK2
T88 522-527 PR:Q5S007 denotes LRRK2
T89 569-576 D012172 denotes retinal
T90 569-576 CHEBI:17898 denotes retinal
T91 569-576 D012172 denotes retinal
T92 569-576 CHEBI:15035 denotes retinal
T93 569-576 CHEBI:45487 denotes retinal
T94 569-589 D012162 denotes retinal degeneration
T95 569-589 D012162 denotes retinal degeneration
T96 605-610 PR:Q5S006 denotes LRRK2
T97 605-610 PR:000003033 denotes LRRK2
T98 605-610 PR:Q5S007 denotes LRRK2
T99 614-619 PR:Q5S006 denotes LRRK2
T100 614-619 PR:000003033 denotes LRRK2
T101 614-619 PR:Q5S007 denotes LRRK2
T102 647-652 UBERON:0007023 denotes adult
T103 771-776 PR:Q5S006 denotes LRRK2
T104 771-776 PR:000003033 denotes LRRK2
T105 771-776 PR:Q5S007 denotes LRRK2
T106 798-810 D020734 denotes parkinsonism
T107 798-810 D020734 denotes parkinsonism
T108 866-875 SO:0000817 denotes wild-type
T109 876-881 PR:Q5S006 denotes LRRK2
T110 876-881 PR:000003033 denotes LRRK2
T111 876-881 PR:Q5S007 denotes LRRK2
T112 898-904 CHEBI:57504 denotes l-DOPA
T113 898-904 D007980 denotes l-DOPA
T114 898-904 D007980 denotes l-DOPA
T115 898-904 CHEBI:15765 denotes l-DOPA
T121 921-926 PR:Q5S006 denotes LRRK2
T122 921-926 PR:000003033 denotes LRRK2
T123 921-926 PR:Q5S007 denotes LRRK2
T125 988-996 10962 denotes tyrosine
T129 988-996 SO:0001446 denotes tyrosine
T132 988-1008 A0A060X6Z0 denotes tyrosine hydroxylase
T131 988-1008 D014446 denotes tyrosine hydroxylase
T133 1071-1075 SO:0001742 denotes gain
T134 1139-1144 PR:Q5S006 denotes LRRK2
T135 1139-1144 PR:000003033 denotes LRRK2
T136 1139-1144 PR:Q5S007 denotes LRRK2
T137 1152-1157 D006801 denotes human
T138 1158-1170 D020734 denotes parkinsonism
T139 1158-1170 D020734 denotes parkinsonism
T140 1178-1183 D004175 denotes flies
T141 1224-1229 PR:Q5S006 denotes LRRK2
T142 1224-1229 PR:000003033 denotes LRRK2
T143 1224-1229 PR:Q5S007 denotes LRRK2
T144 1237-1249 GO:0009405 denotes pathogenesis

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 75-79 DiseaseOrPhenotypicFeature denotes rich 0015404
T2 124-162 DiseaseOrPhenotypicFeature denotes autosomal dominant Parkinson's disease 0011220
T3 164-166 DiseaseOrPhenotypicFeature denotes PD 0008199|0015873|0005180
T6 472-474 DiseaseOrPhenotypicFeature denotes PD 0008199|0015873|0005180
T9 569-589 DiseaseOrPhenotypicFeature denotes retinal degeneration 0004580
T10 1289-1291 DiseaseOrPhenotypicFeature denotes PD 0008199|0015873|0005180

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-49 DRI_Approach denotes A Drosophila model for LRRK2-linked parkinsonism.
T2 50-196 DRI_Challenge denotes Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology.
T3 197-306 DRI_Outcome denotes Previously, we and others found that expression of mutant LRRK2 causes neuronal degeneration in cell culture.
T4 307-475 DRI_Outcome denotes Here we used the GAL4/UAS system to generate transgenic Drosophila expressing either wild-type human LRRK2 or LRRK2-G2019S, the most common mutation associated with PD.
T5 476-590 DRI_Background denotes Expression of either wild-type human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal degeneration.
T6 591-742 DRI_Background denotes Expression of LRRK2 or LRRK2-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality.
T7 743-882 DRI_Challenge denotes Expression of mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than expression of equivalent levels of wild-type LRRK2.
T8 883-1026 DRI_Challenge denotes Treatment with l-DOPA improved mutant LRRK2-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase-positive neurons.
T9 1027-1171 DRI_Outcome denotes To our knowledge, this is the first in vivo"gain-of-function" model which recapitulates several key features of LRRK2-linked human parkinsonism.
T10 1172-1305 DRI_Challenge denotes These flies may provide a useful model for studying LRRK2-linked pathogenesis and for future therapeutic screens for PD intervention.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 50-196 DRI_Approach denotes Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology.
T2 197-306 DRI_Outcome denotes Previously, we and others found that expression of mutant LRRK2 causes neuronal degeneration in cell culture.
T3 307-475 DRI_Outcome denotes Here we used the GAL4/UAS system to generate transgenic Drosophila expressing either wild-type human LRRK2 or LRRK2-G2019S, the most common mutation associated with PD.
T4 476-590 DRI_Background denotes Expression of either wild-type human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal degeneration.
T5 591-742 DRI_Background denotes Expression of LRRK2 or LRRK2-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality.
T6 743-882 DRI_Challenge denotes Expression of mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than expression of equivalent levels of wild-type LRRK2.
T7 883-1026 DRI_Challenge denotes Treatment with l-DOPA improved mutant LRRK2-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase-positive neurons.
T8 1027-1171 DRI_Outcome denotes To our knowledge, this is the first in vivo"gain-of-function" model which recapitulates several key features of LRRK2-linked human parkinsonism.
T9 1172-1305 DRI_Challenge denotes These flies may provide a useful model for studying LRRK2-linked pathogenesis and for future therapeutic screens for PD intervention.